» Articles » PMID: 15537655

Adipogenic Transcriptional Regulation of Hepatic Stellate Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Nov 13
PMID 15537655
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic stellate cells (HSC) undergo transdifferentiation (activation) from lipid-storing pericytes to myofibroblastic cells to participate in liver fibrogenesis. Our recent work demonstrates that depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) constitutes one of the key molecular events for HSC activation and that ectopic expression of this nuclear receptor achieves the phenotypic reversal of activated HSC to the quiescent cells. The present study extends these findings to test a novel hypothesis that adipogenic transcriptional regulation is required for the maintenance of HSC quiescence. Comparative analysis of quiescent and activated HSC in culture reveals higher expression of putative adipogenic transcription factors such as CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPbeta, C/EBPdelta, PPARgamma, liver X receptor alpha, sterol regulatory element-binding protein 1c and of adipocyte-specific genes in the quiescent cells. Conversely, activated HSC have increased expression of PPARbeta, a transcription factor known to promote fatty acid oxidation. A treatment of activated HSC with the adipocyte differentiation mixture (isobutylmethylxanthine, dexamethasone, and insulin) or ectopic expression of PPARgamma or SREBP-1c in these cells, induces a panel of adipogenic transcription factors, reduces PPARbeta, and causes the phenotypic reversal to quiescent HSC. These results support the importance of adipogenic transcriptional regulation in HSC quiescence and provide a new framework for identifying novel molecular targets for the treatment of liver cirrhosis.

Citing Articles

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.

Biagioli M, Fiorucci S Liver Res. 2025; 5(3):119-141.

PMID: 39957845 PMC: 11791866. DOI: 10.1016/j.livres.2021.08.003.


The effect and application of adiponectin in hepatic fibrosis.

Chen T, Yang W, Dong R, Yao H, Sun M, Wang J Gastroenterol Rep (Oxf). 2024; 12:goae108.

PMID: 39737222 PMC: 11683834. DOI: 10.1093/gastro/goae108.


Biomimetic mesenchymal stem cell membrane-coated nanoparticle delivery of MKP5 inhibits hepatic fibrosis through the IRE/XBP1 pathway.

Tian Y, Sun D, Liu N, Zhao J, Zhao T, Liu X J Nanobiotechnology. 2024; 22(1):741.

PMID: 39609656 PMC: 11606114. DOI: 10.1186/s12951-024-03029-8.


ATF3-mediated transactivation of CXCL14 in HSCs during liver fibrosis.

Li X, Lin L, Li Y, Zhang W, Lang Z, Zheng J Clin Transl Med. 2024; 14(10):e70040.

PMID: 39358917 PMC: 11446984. DOI: 10.1002/ctm2.70040.


Purinergic Signaling in Non-Parenchymal Liver Cells.

Mata-Martinez E, Ramirez-Ledesma M, Vazquez-Victorio G, Hernandez-Munoz R, Diaz-Munoz M, Vazquez-Cuevas F Int J Mol Sci. 2024; 25(17).

PMID: 39273394 PMC: 11394727. DOI: 10.3390/ijms25179447.